Search

Your search keyword '"Yoshihara, Satoshi"' showing total 451 results
Start Over Author "Yoshihara, Satoshi"
451 results on '"Yoshihara, Satoshi"'

1. The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients

Author

Shimazu, Yutaka, Kanda, Junya, Takakuwa, Teruhito, Onda, Yoshiyuki, Fukushima, Kentaro, Hotta, Masaaki, Fuchida, Shin-ichi, Uoshima, Nobuhiko, Shimura, Yuji, Tanaka, Hirokazu, Ohta, Kensuke, Shibayama, Hirohiko, Kosugi, Satoru, Yagi, Hideo, Yoshihara, Satoshi, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Matsumura, Itaru, Kuroda, Junya, Takaori-Kondo, Akifumi, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

2. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia

Author

Nakamura, Yukinori, Zaimoku, Yoshitaka, Yamaguchi, Hiroki, Yamazaki, Hirohito, Kanaya, Minoru, Uchida, Naoyuki, Doki, Noriko, Sakurai, Masatoshi, Hiramoto, Nobuhiro, Kako, Shinichi, Onizuka, Makoto, Onodera, Koichi, Maruyama, Yumiko, Ohigashi, Hiroyuki, Nishida, Tetsuya, Yoshihara, Satoshi, Matsuoka, Ken-ichi, Eto, Tetsuya, Kanda, Yoshinobu, Fukuda, Takahiro, Atsuta, Yoshiko, and Onishi, Yasushi

Published
2024
Full Text
View/download PDF

4. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

Author

Nakamura, Naokazu, Arima, Nobuyoshi, Takakuwa, Teruhito, Yoshioka, Satoshi, Imada, Kazunori, Fukushima, Kentaro, Hotta, Masaaki, Fuchida, Shin-ichi, Kanda, Junya, Uoshima, Nobuhiko, Shimura, Yuji, Tanaka, Hirokazu, Ohta, Kensuke, Kosugi, Satoru, Yagi, Hideo, Yoshihara, Satoshi, Yamamura, Ryosuke, Adachi, Yoko, Hanamoto, Hitoshi, Shibayama, Hirohiko, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, Kuroda, Junya, Matsumura, Itaru, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

5. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission

Author

Yanada, Masamitsu, Yamasaki, Satoshi, Kondo, Tadakazu, Kawata, Takahito, Harada, Kaito, Uchida, Naoyuki, Doki, Noriko, Yoshihara, Satoshi, Katayama, Yuta, Eto, Tetsuya, Tanaka, Masatsugu, Takada, Satoru, Kawakita, Toshiro, Nishida, Tetsuya, Ota, Shuichi, Serizawa, Kentaro, Onizuka, Makoto, Kanda, Yoshinobu, Fukuda, Takahiro, Atsuta, Yoshiko, and Konuma, Takaaki

Published
2024
Full Text
View/download PDF

6. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

Author

Shimazu, Yutaka, Kanda, Junya, Onda, Yoshiyuki, Fuchida, Shin-ichi, Ohta, Kensuke, Shimura, Yuji, Kosugi, Satoru, Yamamura, Ryosuke, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Adachi, Yoko, Anzai, Naoyuki, Hotta, Masaaki, Fukushima, Kentaro, Yagi, Hideo, Yoshihara, Satoshi, Tanaka, Yasuhiro, Takakuwa, Teruhito, Tanaka, Hirokazu, Shibayama, Hirohiko, Uoshima, Nobuhiko, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Matsumura, Itaru, Kuroda, Junya, Takaori-Kondo, Akifumi, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

8. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum

Author

Shimura, Yuji, Shibayama, Hirohiko, Nakaya, Aya, Yamamura, Ryosuke, Imada, Kazunori, Kaneko, Hitomi, Hanamoto, Hitoshi, Fuchida, Shin-ichi, Tanaka, Hirokazu, Kosugi, Satoru, Kiyota, Miki, Matsui, Toshimitsu, Kanda, Junya, Iida, Masato, Matsuda, Mitsuhiro, Uoshima, Nobuhiko, Shibano, Masaru, Karasuno, Takahiro, Hamada, Tsuneyoshi, Ohta, Kensuke, Ito, Tomoki, Yagi, Hideo, Yoshihara, Satoshi, Shimazaki, Chihiro, Nomura, Shosaku, Hino, Masayuki, Takaori-Kondo, Akifumi, Matsumura, Itaru, Kanakura, Yuzuru, and Kuroda, Junya

Published
2023
Full Text
View/download PDF

9. Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial

Author

Nakamura, Toru, Masuda, Atsutaka, Kako, Makoto, Enomoto, Hirayuki, Kaibori, Masaki, Fujita, Yasuyuki, Tanizawa, Kyoko, Ioji, Tetsuya, Fujimori, Yoshihiro, Fukami, Kei, Hazama, Takuma, Iwamoto, Hideki, Kako, Yasukazu, Kobayashi, Kaoru, Koga, Hironori, Nagafuji, Koji, Ohtake, Takayasu, Suzuki, Hiroyuki, Takashima, Tomoyuki, Tsukiyama, Toshitaka, Uojima, Haruki, Yamahara, Kenichi, Yamakado, Koichiro, Yamamoto, Hidekazu, Yoh, Kazunori, Yoshihara, Satoshi, Kawamoto, Atsuhiko, Nishiguchi, Shuhei, Kobayashi, Shuzo, Torimura, Takuji, and Kawaguchi, Takumi

Published
2024
Full Text
View/download PDF

10. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Published
2023
Full Text
View/download PDF

12. Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

Author

Jo, Tomoyasu, Yoshihara, Kyoko, Ri, Masaki, Tsukada, Nobuhiro, Mimura, Naoya, Fujii, Keiko, Fukushima, Kentaro, Fujiwara, Shin-ichiro, Shimura, Yuji, Haraguchi, Kyoko, Kato, Koji, Satake, Atsushi, Yoshida, Akiyo, Suzuki, Rikio, Ikemoto, Junko, Iwaki, Keita, Takeda, Wataru, Yonetani, Noboru, Tanosaki, Ryuji, Yamada-Fujiwara, Minami, Kahata, Kaoru, Nagamura-Inoue, Tokiko, Yoshihara, Satoshi, and Arai, Yasuyuki

Published
2024
Full Text
View/download PDF

13. Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation

Author

Tamaki, Masaharu, Kawamura, Shunto, Takano, Kosuke, Nakamae, Hirohisa, Doki, Noriko, Ohigashi, Hiroyuki, Maruyama, Yumiko, Ota, Shuichi, Hiramoto, Nobuhiro, Eto, Tetsuya, Yoshihara, Satoshi, Matsuoka, Ken-ichi, Masuko, Masayoshi, Onizuka, Makoto, Kanda, Yoshinobu, Fukuda, Takahiro, Atsuta, Yoshiko, Yanagisawa, Ryu, Yakushijin, Kimikazu, and Nakasone, Hideki

Published
2024
Full Text
View/download PDF

14. Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry

Author

Kanda, Junya, Mitsuyoshi, Takaya, Sakurai, Masatoshi, Nishimori, Hisakazu, Murata, Makoto, Uchida, Naoyuki, Doki, Noriko, Inamoto, Yoshihiro, Nishida, Tetsuya, Tanaka, Masatsugu, Katayama, Yuta, Eto, Tetsuya, Matsuoka, Ken-ichi, Yoshihara, Satoshi, Sawa, Masashi, Kawakita, Toshiro, Jun, Gyungjin, Kurata, Mio, Ichinohe, Tatsuo, Fukuda, Takahiro, Teshima, Takanori, Atsuta, Yoshiko, and Terakura, Seitaro

Published
2024
Full Text
View/download PDF

15. Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation

Author

Teramoto, Masahiro, Maruyama, Satoshi, Tamaki, Hiroya, Kaida, Katsuji, Mayumi, Azusa, Fukunaga, Keiko, Inoue, Takayuki, Yoshihara, Kyoko, Yoshihara, Satoshi, Ikegame, Kazuhiro, Okada, Masaya, Osugi, Yuko, Ogawa, Hiroyasu, Higasa, Satoshi, Morita, Kunihiko, Matsumoto, Kana, and Kijima, Takashi

Published
2022
Full Text
View/download PDF

16. Expression of activated integrin β7 in multiple myeloma patients

Author

Hosen, Naoki, Yoshihara, Satoshi, Takamatsu, Hiroyuki, Ri, Masaki, Nagata, Yasuyuki, Kosugi, Hiroshi, Shimomura, Yoshimitsu, Hanamura, Ichiro, Fuji, Shigeo, Minauchi, Koichiro, Kuroda, Junya, Suzuki, Rikio, Nishimura, Noriko, Uoshima, Nobuhiko, Nakamae, Hirohisa, Kawano, Yawara, Mizuno, Ishikazu, Gomyo, Hiroshi, Suzuki, Kenshi, Ozaki, Shuji, Nakamura, Shingen, Imai, Yoichi, Kizaki, Masahiro, Negoro, Eiju, Handa, Hiroshi, and Iida, Shinsuke

Published
2021
Full Text
View/download PDF

17. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Author

Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, null, null, Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, and null, null

Abstract

PURPOSEAllogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit.METHODSAdults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS.RESULTSThree hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P =.0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P =.0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P =.575).CONCLUSIONAlthough the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Published
2024

19. RhD mismatch does not affect haematopoietic recovery, graft‐versus‐host disease and survival in allogeneic haematopoietic cell transplantation: A Japanese registry‐based study.

Author

Konuma, Takaaki, Uchida, Naoyuki, Takeda, Wataru, Doki, Noriko, Yoshihara, Satoshi, Nishida, Tetsuya, Kuriyama, Takuro, Tanaka, Masatsugu, Ohigashi, Hiroyuki, Nakamae, Hirohisa, Katayama, Yuta, Ota, Shuichi, Hashii, Yoshiko, Ishimaru, Fumihiko, Fukuda, Takahiro, Ohbiki, Marie, and Atsuta, Yoshiko

Subjects
CELL transplantation, GRAFT versus host disease, OVERALL survival, HEMATOPOIETIC stem cell transplantation, STEM cell transplantation, ABO blood group system, ERYTHROCYTES
Abstract

Background and Objectives: ABO blood group mismatch between the donor and the recipient can affect the success of the transplant as well as problems with the red blood cells during allogeneic haematopoietic cell transplantation (HCT). However, the impact of the Rhesus (Rh) D mismatch on transplant outcomes in allogeneic HCT has been poorly elucidated. Materials and Methods: We retrospectively evaluated the impact of the RhD mismatch on post‐transplant outcomes in 64,923 patients who underwent allogeneic HCT between 2000 and 2021 using a Japanese registry database. Results: Out of the whole group, 64,293, 322, 270 and 38 HCTs were done when the recipient or donor was RhD‐mismatched with (+/+), (−/+), (+/−) or (−/−) combinations. The difference in RhD between recipient/donor (−/+), (+/−) and (−/−) did not affect haematopoietic recovery, acute and chronic graft‐versus‐host disease (GVHD), overall survival (OS), non‐relapse mortality (NRM) or relapse when RhD (+/+) was used as the reference group in multivariate analysis. Conclusion: Our registry‐based study demonstrated that RhD mismatch between recipient and donor did not significantly impact haematopoietic recovery, GVHD, OS, NRM or relapse after allogeneic HCT. These data suggest that RhD mismatches may not need to be avoided for recipient and donor combinations in allogeneic HCT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Individualized rabbit anti‐thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with high‐risk hematologic malignancy: Exposure–response analysis and population pharmacokinetics simulations

Author

Teramoto, Masahiro, primary, Takahashi, Takuto, additional, Matsumoto, Kana, additional, Jaber, Mutaz, additional, Kaida, Katsuji, additional, Tamaki, Hiroya, additional, Ikegame, Kazuhiro, additional, and Yoshihara, Satoshi, additional

Published
2024
Full Text
View/download PDF

21. Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study

Author

Ikegame, Kazuhiro, Kaida, Katsuji, Fukunaga, Keiko, Osugi, Yuko, Yoshihara, Kyoko, Yoshihara, Satoshi, Ishii, Shinichi, Fujino, Satoshi, Yamashita, Takaya, Mayumi, Azusa, Maruyama, Satoshi, Teramoto, Masahiro, Inoue, Takayuki, Okada, Masaya, Tamaki, Hiroya, Ogawa, Hiroyasu, and Fujimori, Yosihiro

Published
2021
Full Text
View/download PDF

23. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission

Author

Yanada, Masamitsu, primary, Yamasaki, Satoshi, additional, Kondo, Tadakazu, additional, Kawata, Takahito, additional, Harada, Kaito, additional, Uchida, Naoyuki, additional, Doki, Noriko, additional, Yoshihara, Satoshi, additional, Katayama, Yuta, additional, Eto, Tetsuya, additional, Tanaka, Masatsugu, additional, Takada, Satoru, additional, Kawakita, Toshiro, additional, Nishida, Tetsuya, additional, Ota, Shuichi, additional, Serizawa, Kentaro, additional, Onizuka, Makoto, additional, Kanda, Yoshinobu, additional, Fukuda, Takahiro, additional, Atsuta, Yoshiko, additional, and Konuma, Takaaki, additional

Published
2023
Full Text
View/download PDF

24. 本邦における造血幹細胞採取等のアフェレーシスの実態調査

Author

Yakushijin, Kimikazu, primary, Yoshihara, Satoshi, additional, Ikemoto, Junko, additional, Ikeda, Kazuhiko, additional, Ishida, Akaru, additional, Ohto, Hitoshi, additional, Ohara, Akira, additional, Kajiwara, Michiko, additional, Kikuta, Atsushi, additional, Haraguchi, Kyoko, additional, Fujiwara, Shin-ichiro, additional, Yamada-Fujiwara, Minami, additional, Yamazaki, Rie, additional, Nagamura-Inoue, Tokiko, additional, Tanosaki, Ryuji, additional, Okuyama, Yoshiki, additional, Fujimori, Yoshihiro, additional, and Ueda, Yasunori, additional

Published
2023
Full Text
View/download PDF

26. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

Author

Ochi, Yotaro, Yoshida, Kenichi, Huang, Ying-Jung, Kuo, Ming-Chung, Nannya, Yasuhito, Sasaki, Ko, Mitani, Kinuko, Hosoya, Noriko, Hiramoto, Nobuhiro, Ishikawa, Takayuki, Branford, Susan, Shanmuganathan, Naranie, Ohyashiki, Kazuma, Takahashi, Naoto, Takaku, Tomoiku, Tsuchiya, Shun, Kanemura, Nobuhiro, Nakamura, Nobuhiko, Ueda, Yasunori, Yoshihara, Satoshi, Bera, Rabindranath, Shiozawa, Yusuke, Zhao, Lanying, Takeda, June, Watatani, Yosaku, Okuda, Rurika, Makishima, Hideki, Shiraishi, Yuichi, Chiba, Kenichi, Tanaka, Hiroko, Sanada, Masashi, Takaori-Kondo, Akifumi, Miyano, Satoru, Ogawa, Seishi, and Shih, Lee-Yung

Published
2021
Full Text
View/download PDF

28. A case of non‐Hodgkin lymphoma of the upper gingiva with minimal residual disease detected in cryopreserved ovarian tissue: A case report.

Author

Wakimoto, Ken, Wakimoto, Yu, Matsuda, Ikuo, Yoshihara, Satoshi, Ukita, Yuji, Fukui, Atushi, Hirota, Seiichi, and Shibahara, Hiroaki

Subjects
BIOPSY, B cell lymphoma, CANCER patients, NON-Hodgkin's lymphoma, GINGIVA, CRYOPRESERVATION of organs, tissues, etc.
Abstract

Recently, more than 200 live births following ovarian tissue cryopreservation (OTC) and transplantation in cancer survivors have been reported worldwide. However, cancer survivors with minimal residual disease (MRD) in cryopreserved ovarian tissue are at the risk of relapse through the graft. Here, we report a rare case of a 19‐year‐old female patient with non‐Hodgkin lymphoma who had MRD in the ovary harvested for OTC. The patient was diagnosed with aggressive B‐cell lymphoma after gingival biopsy. The 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan performed before OTC showed no viable lesions in either ovary. However, on histological evaluation, we detected infiltration of lymphoma cells in the ovary. Informed consent about MRD is required even if there is no evidence of MRD in the ovary before OTC. Patients whose cryopreserved ovaries have MRD may require the development of alternative assisted reproductive technologies such as in vitro growth or artificial ovary. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy

Author

Jo, Tomoyasu, Yoshihara, Satoshi, Hada, Asuka, Arai, Yasuyuki, Kitawaki, Toshio, Ikemoto, Junko, Onomoto, Hitomi, Sugiyama, Hiroki, Yoshihara, Kyoko, Obi, Natsuno, Matsui, Keiko, Niwa, Norimi, Nakagawa, Yoko, Kanda, Junya, Kondo, Tadakazu, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Adachi, Souichi, Takita, Junko, Takaori-Kondo, Akifumi, and Nagao, Miki

Published
2022
Full Text
View/download PDF

32. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Author

Okada, Masaya, Imagawa, Jun, Tanaka, Hideo, Nakamae, Hirohisa, Hino, Masayuki, Murai, Kazunori, Ishida, Yoji, Kumagai, Takashi, Sato, Seiichi, Ohashi, Kazuteru, Sakamaki, Hisashi, Wakita, Hisashi, Uoshima, Nobuhiko, Nakagawa, Yasunori, Minami, Yosuke, Ogasawara, Masahiro, Takeoka, Tomoharu, Akasaka, Hiroshi, Utsumi, Takahiko, Uike, Naokuni, Sato, Tsutomu, Ando, Sachiko, Usuki, Kensuke, Mizuta, Syuichi, Hashino, Satoshi, Nomura, Tetsuhiko, Shikami, Masato, Fukutani, Hisashi, Ohe, Yokiko, Kosugi, Hiroshi, Shibayama, Hirohiko, Maeda, Yasuhiro, Fukushima, Toshihiro, Yamazaki, Hirohito, Tsubaki, Kazuo, Kukita, Toshimasa, Adachi, Yoko, Nataduka, Toshiki, Sakoda, Hiroto, Yokoyama, Hisayuki, Okamoto, Takahiro, Shirasugi, Yukari, Onishi, Yasushi, Nohgawa, Masaharu, Yoshihara, Satoshi, Morita, Satoshi, Sakamoto, Junichi, and Kimura, Shinya

Published
2018
Full Text
View/download PDF

34. Induction of WT1 (Wilms' Tumor Gene)-Specific Cytotoxic T Lymphocytes by WT1 Peptide Vaccine and the Resultant Cancer Regression

Author

Oka, Yoshihiro, Tsuboi, Akihiro, Taguchi, Tetsuya, Osaki, Tadashi, Kyo, Taiichi, Nakajima, Hiroko, Elisseeva, Olga A., Oji, Yusuke, Kawakami, Manabu, Ikegame, Kazuhiro, Hosen, Naoki, Yoshihara, Satoshi, Wu, Fei, Fujiki, Fumihiro, Murakami, Masaki, Masuda, Tomoki, Nishida, Sumiyuki, Shirakata, Toshiaki, Nakatsuka, Shin-ichi, Sasaki, Ayako, Udaka, Keiko, Dohy, Hiroo, Aozasa, Katsuyuki, Noguchi, Shinzaburo, Kawase, Ichiro, Sugiyama, Haruo, and Sugimura, Takashi

Published
2004

35. P424: LANDSCAPE OF CHROMATIN ACCESSIBILITY IN ACUTE MYELOID LEUKEMIA

Author

Ochi, Yotaro, primary, Nannya, Yasuhito, additional, Kasahara, Senji, additional, Hiramoto, Nobuhiro, additional, Kanemura, Nobuhiro, additional, Sezaki, Nobuo, additional, Sakurada, Maki, additional, Iwasaki, Makoto, additional, Kanda, Junya, additional, Ueda, Yasunori, additional, Yoshihara, Satoshi, additional, Nakagawa, Masahiro, additional, Saiki, Ryunosuke, additional, Yoda, Akinori, additional, Okuda, Rurika, additional, Motomura, Masanori, additional, Shiraishi, Yuichi, additional, Ishikawa, Takayuki, additional, Miyano, Satoru, additional, Takaori, Akifumi, additional, and Ogawa, Seishi, additional

Published
2023
Full Text
View/download PDF

36. Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

Author

Jo, Tomoyasu, primary, Yoshihara, Satoshi, additional, Okuyama, Yoshiki, additional, Fujii, Keiko, additional, Henzan, Tomoko, additional, Kahata, Kaoru, additional, Yamazaki, Rie, additional, Takeda, Wataru, additional, Umezawa, Yoshihiro, additional, Fukushima, Kentaro, additional, Ashida, Takashi, additional, Yamada‐Fujiwara, Minami, additional, Hanajiri, Ryo, additional, Yonetani, Noboru, additional, Tada, Yuma, additional, Shimura, Yuji, additional, Nishikii, Hidekazu, additional, Shiba, Norio, additional, Mimura, Naoya, additional, Ando, Jun, additional, Sato, Takayuki, additional, Nakashima, Yasuhiro, additional, Ikemoto, Junko, additional, Iwaki, Keita, additional, Fujiwara, Shin‐ichiro, additional, Ri, Masaki, additional, Nagamura‐Inoue, Tokiko, additional, Tanosaki, Ryuji, additional, and Arai, Yasuyuki, additional

Published
2023
Full Text
View/download PDF

37. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

Author

10826564, Jo, Tomoyasu, Yoshihara, Satoshi, Okuyama, Yoshiki, Fujii, Keiko, Henzan, Tomoko, Kahata, Kaoru, Yamazaki, Rie, Takeda, Wataru, Umezawa, Yoshihiro, Fukushima, Kentaro, Ashida, Takashi, Yamada‐Fujiwara, Minami, Hanajiri, Ryo, Yonetani, Noboru, Tada, Yuma, Shimura, Yuji, Nishikii, Hidekazu, Shiba, Norio, Mimura, Naoya, Ando, Jun, Sato, Takayuki, Nakashima, Yasuhiro, Ikemoto, Junko, Iwaki, Keita, Fujiwara, Shin‐ichiro, Ri, Masaki, Nagamura‐Inoue, Tokiko, Tanosaki, Ryuji, Arai, Yasuyuki, 10826564, Jo, Tomoyasu, Yoshihara, Satoshi, Okuyama, Yoshiki, Fujii, Keiko, Henzan, Tomoko, Kahata, Kaoru, Yamazaki, Rie, Takeda, Wataru, Umezawa, Yoshihiro, Fukushima, Kentaro, Ashida, Takashi, Yamada‐Fujiwara, Minami, Hanajiri, Ryo, Yonetani, Noboru, Tada, Yuma, Shimura, Yuji, Nishikii, Hidekazu, Shiba, Norio, Mimura, Naoya, Ando, Jun, Sato, Takayuki, Nakashima, Yasuhiro, Ikemoto, Junko, Iwaki, Keita, Fujiwara, Shin‐ichiro, Ri, Masaki, Nagamura‐Inoue, Tokiko, Tanosaki, Ryuji, and Arai, Yasuyuki

Published
2023

38. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

30636311, Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, Kuroda, Junya, 30636311, Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Published
2023

39. Epigenetic Classification of Acute Myeloid Leukemia Revealed By Genome-Wide Chromatin Profiling

Author

Ochi, Yotaro, Nannya, Yasuhito, Liew-Littorin, Markus, Kasahara, Senji, Hiramoto, Nobuhiro, Kanemura, Nobuhiro, Sezaki, Nobuo, Sakurada, Maki, Iwasaki, Makoto, Kanda, Junya, Ueda, Yasunori, Yoshihara, Satoshi, Osterroos, Albin, Motomura, Masanori, Nakagawa, Masahiro Marshall, Saiki, Ryunosuke, Yoda, Akinori, Okuda, Rurika, Shiraishi, Yuichi, Ishikawa, Takayuki, Miyano, Satoru, Takaori-Kondo, Akifumi, Lehmann, Soren, Ogawa, Seishi, Ochi, Yotaro, Nannya, Yasuhito, Liew-Littorin, Markus, Kasahara, Senji, Hiramoto, Nobuhiro, Kanemura, Nobuhiro, Sezaki, Nobuo, Sakurada, Maki, Iwasaki, Makoto, Kanda, Junya, Ueda, Yasunori, Yoshihara, Satoshi, Osterroos, Albin, Motomura, Masanori, Nakagawa, Masahiro Marshall, Saiki, Ryunosuke, Yoda, Akinori, Okuda, Rurika, Shiraishi, Yuichi, Ishikawa, Takayuki, Miyano, Satoru, Takaori-Kondo, Akifumi, Lehmann, Soren, and Ogawa, Seishi

Published
2023
Full Text
View/download PDF

41. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

Author

Nakaya, Aya, primary, Shibayama, Hirohiko, additional, Uoshima, Nobuhiko, additional, Yamamura, Ryosuke, additional, Yoshioka, Satoshi, additional, Imada, Kazunori, additional, Shimura, Yuji, additional, Hotta, Masaaki, additional, Matsui, Toshimitsu, additional, Kosugi, Satoru, additional, Hanamoto, Hitoshi, additional, Uchiyama, Hitoji, additional, Yoshihara, Satoshi, additional, Fuchida, Shin-ichi, additional, Onda, Yoshiyuki, additional, Tanaka, Yasuhiro, additional, Ohta, Kensuke, additional, Matsuda, Mitsuhiro, additional, Kanda, Junya, additional, Yoko, Adachi, additional, Kiyota, Miki, additional, Kawata, Eri, additional, Takahashi, Ryoichi, additional, Fukushima, Kentaro, additional, Tanaka, Hirokazu, additional, Yagi, Hideo, additional, Takakuwa, Teruhito, additional, Hosen, Naoki, additional, Ito, Tomoki, additional, Shimazaki, Chihiro, additional, Takaori-Kondo, Akifumi, additional, Kuroda, Junya, additional, Matsumura, Itaru, additional, and Hino, Masayuki, additional

Published
2023
Full Text
View/download PDF

42. Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non–Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan

Author

Ikegame, Kazuhiro, Yoshida, Takashi, Yoshihara, Satoshi, Daimon, Takashi, Shimizu, Hiroaki, Maeda, Yoshinobu, Ueda, Yasunori, Kaida, Katsuji, Ishii, Shinichi, Taniguchi, Kyoko, Okada, Masaya, Tamaki, Hiroya, Okumura, Hirokazu, Kaya, Hiroyasu, Kurokawa, Toshiro, Kodera, Yoshihisa, Taniguchi, Shuichi, Kanda, Yoshinobu, and Ogawa, Hiroyasu

Published
2015
Full Text
View/download PDF

43. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone

Author

YOROIDAKA, TAKESHI, primary, YAMASHITA, TAKESHI, additional, MURATA, RYOICHI, additional, YOSHIHARA, KYOKO, additional, YOSHIHARA, SATOSHI, additional, UEDA, MIKIO, additional, NAKAO, SHINJI, additional, MATSUE, KOSEI, additional, and TAKAMATSU, HIROYUKI, additional

Published
2022
Full Text
View/download PDF

44. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

Shimazu, Yutaka, primary, Kanda, Junya, additional, Kosugi, Satoru, additional, Ito, Tomoki, additional, Kaneko, Hitomi, additional, Imada, Kazunori, additional, Shimura, Yuji, additional, Fuchida, Shin-ichi, additional, Fukushima, Kentaro, additional, Tanaka, Hirokazu, additional, Yoshihara, Satoshi, additional, Ohta, Kensuke, additional, Uoshima, Nobuhiko, additional, Yagi, Hideo, additional, Shibayama, Hirohiko, additional, Yamamura, Ryosuke, additional, Tanaka, Yasuhiro, additional, Uchiyama, Hitoji, additional, Onda, Yoshiyuki, additional, Adachi, Yoko, additional, Hanamoto, Hitoshi, additional, Takahashi, Ryoichi, additional, Matsuda, Mitsuhiro, additional, Miyoshi, Takashi, additional, Takakuwa, Teruhito, additional, Hino, Masayuki, additional, Hosen, Naoki, additional, Nomura, Shosaku, additional, Shimazaki, Chihiro, additional, Matsumura, Itaru, additional, Takaori-Kondo, Akifumi, additional, and Kuroda, Junya, additional

Published
2022
Full Text
View/download PDF

45. Spousal hematopoietic stem cell transplantation

Author

Ikegame, Kazuhiro, Kaida, Katsuji, Yoshihara, Satoshi, Yoshihara, Kyoko, Ishii, Shinichi, Inoue, Takayuki, Okada, Masaya, Tamaki, Hiroya, Soma, Toshihiro, Kusunoki, Yasushi, Kojima, Hiroto, Saji, Hiroh, and Ogawa, Hiroyasu

Published
2017
Full Text
View/download PDF

46. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Subjects
Multidisciplinary, Tumour immunology, Immunotherapy, Lymphocytes, Translational research, Predictive markers
Abstract

Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing a real-world database in Japan. We analyzed 179 patients who underwent 201 elotuzumab treatments. The median time to next treatment (TTNT) with the 95% confidence interval was 6.29 months (5.18–9.20) in this cohort. Univariate analysis showed that patients with any of the following had longer TTNT: no high risk cytogenic abnormalities, more white blood cells, more lymphocytes, non-deviated κ/λ ratio, lower β2 microglobulin levels (B2MG), fewer prior drug regimens, no prior daratumumab use and better response after elotuzumab treatment. A multivariate analysis showed that TTNT was longer in patients with more lymphocytes (≥ 1400/μL), non-deviated κ/λ ratio (0.1–10), lower B2MG (p p

Published
2022

47. Thrombocytopenia and Low CD4/CD8 Ratio at Apheresis Along with Prior Bendamustine Use Increase Risk of CAR-T Cell Manufacturing Failure

Author

Jo, Tomoyasu, primary, Arai, Yasuyuki, additional, Yoshihara, Satoshi, additional, Kojima, Minoru, additional, Ikemoto, Junko, additional, Uemura, Tomoe, additional, Iwaki, Keita, additional, Yonetani, Noboru, additional, Fujiwara, Shin-ichiro, additional, Ri, Masaki, additional, Kahata, Kaoru, additional, Nagamura-Inoue, Tokiko, additional, Yamada-Fujiwara, Minami, additional, and Tanosaki, Ryuji, additional

Published
2022
Full Text
View/download PDF

48. ESTABLISHMENT OF A SUSTAINABLE CAR T-CELL THERAPY OPERATION SYSTEM BY UTILIZING THE ALREADY-EXISTING STRUCTURE AT THE BLOOD TRANSFUSION DIVISION

Author

Ikemoto, Junko, primary, Yoshihara, Satoshi, additional, Yamashita, Izumi, additional, Tsujimoto, Mao, additional, Yamaguchi, Fuka, additional, Harada, Yuki, additional, Sugiyama, Hiroki, additional, Otsuka, Shinya, additional, Murata, Rie, additional, Onomoto, Hitomi, additional, Okuda, Noriko, additional, Takao, Risa, additional, Ikegami, Asuka, additional, Suita, Mari, additional, Uemura, Ayaka, additional, Kawaguchi, Mariko, additional, Yoshihara, Kyoko, additional, Yamahara, Kenichi, additional, and Higasa, Satoshi, additional

Published
2022
Full Text
View/download PDF

49. This title is unavailable for guests, please login to see more information.

Author

30636311, Shimazu, Yutaka, Kanda, Junya, Kaneko, Hitomi, Imada, Kazunori, Yamamura, Ryosuke, Kosugi, Satoru, Shimura, Yuji, Ito, Tomoki, Fuchida, Shin-ichi, Uchiyama, Hitoji, Fukushima, Kentaro, Yoshihara, Satoshi, Hanamoto, Hitoshi, Tanaka, Hirokazu, Uoshima, Nobuhiko, Ohta, Kensuke, Yagi, Hideo, Shibayama, Hirohiko, Onda, Yoshiyuki, Tanaka, Yasuhiro, Adachi, Yoko, Matsuda, Mitsuhiro, Iida, Masato, Miyoshi, Takashi, Matsui, Toshimitsu, Takahashi, Ryoichi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, Kuroda, Junya, 30636311, Shimazu, Yutaka, Kanda, Junya, Kaneko, Hitomi, Imada, Kazunori, Yamamura, Ryosuke, Kosugi, Satoru, Shimura, Yuji, Ito, Tomoki, Fuchida, Shin-ichi, Uchiyama, Hitoji, Fukushima, Kentaro, Yoshihara, Satoshi, Hanamoto, Hitoshi, Tanaka, Hirokazu, Uoshima, Nobuhiko, Ohta, Kensuke, Yagi, Hideo, Shibayama, Hirohiko, Onda, Yoshiyuki, Tanaka, Yasuhiro, Adachi, Yoko, Matsuda, Mitsuhiro, Iida, Masato, Miyoshi, Takashi, Matsui, Toshimitsu, Takahashi, Ryoichi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Published
2022

50. Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

Author

30636311, Onda, Yoshiyuki, Kanda, Junya, Kaneko, Hitomi, Shimura, Yuji, Fuchida, Shin-Ichi, Nakaya, Aya, Itou, Tomoki, Yamamura, Ryosuke, Tanaka, Hirokazu, Shibayama, Hirohiko, Shimazu, Yutaka, Uchiyama, Hitoji, Yoshihara, Satoshi, Adachi, Yoko, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Uoshima, Nobuhiko, Kosugi, Satoru, Ohta, Kensuke, Yagi, Hideo, Kanakura, Yuzuru, Matsumura, Itaru, Hino, Masayuki, Nomura, Shosaku, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, Kuroda, Junya, 30636311, Onda, Yoshiyuki, Kanda, Junya, Kaneko, Hitomi, Shimura, Yuji, Fuchida, Shin-Ichi, Nakaya, Aya, Itou, Tomoki, Yamamura, Ryosuke, Tanaka, Hirokazu, Shibayama, Hirohiko, Shimazu, Yutaka, Uchiyama, Hitoji, Yoshihara, Satoshi, Adachi, Yoko, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Uoshima, Nobuhiko, Kosugi, Satoru, Ohta, Kensuke, Yagi, Hideo, Kanakura, Yuzuru, Matsumura, Itaru, Hino, Masayuki, Nomura, Shosaku, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, and Kuroda, Junya

Abstract

Background: Little is known about the real-world survival benefits and safety profiles of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their efficacy and safety in 157 patients registered in the Kansai Myeloma Forum database. Results: A total of 107 patients received KRd. Before KRd, 99% of patients had received bortezomib (54% were refractory disease), and 82% had received lenalidomide (57% were refractory disease). The overall response rate (ORR) was 68.2%. The median progression-free survival (PFS) and overall survival (OS) were 8.8 and 29.3 months, respectively. Multivariate analysis showed that reduction of the carfilzomib dose and non-IgG M protein were significantly associated with lower PFS and reduction of the carfilzomib dose and refractoriness to prior bortezomib-based regimens were significantly associated with lower OS. A total of 50 patients received Kd. Before Kd, 96% of patients had received bortezomib (54% were refractory disease). The ORR was 62.0%. The median PFS and OS were 7.1 and 20.9 months, respectively. Based on the multivariate analysis, reduction of the carfilzomib dose and International Staging System Stage III (ISS III) were significantly associated with lower PFS. Grade III or higher adverse events were observed in 48% of KRd cases and 54% of Kd cases. Cardiovascular events, cytopenia, and infections were frequent, and 4 KRd patients died due to heart failure, arrhythmia, cerebral hemorrhage, and pneumonia. Conclusion: Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting. Adverse effects after KRd and Kd therapy should also be considered.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results